
In a matter of days, Novo A/S has shedded a biotech company and assumed control of a medtech company, but CEO Eivind Kolding denies speculation that the investment group behind Novo Nordisk and Novozymes is moving away from biotech altogether. It is rather a matter of Novo being able to tick off all its criteria for new acquisitions.
The newest member of the Novo family, Sonion, is a global market leader within micro acoustic components for use in hearing instruments, and the company fits Novo’s new strategy like a glove.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app